Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
University of California, San Francisco · Düsseldorf University Hospital · +12 more institutions
Abstract
B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells.
In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end point was the annualized relapse rate.
-weighted magnetic resonance scan was 0.02 with ocrelizumab versus 0.29 with interferon beta-1a in trial 1 (94% lower number of lesions with ocrelizumab, P
Citation impact
- FWCI
- 113.95
- Percentile
- 100%
- References
- 39
Authors
21- SLStephen L. HauserCorresponding
University of California, San Francisco, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, University of British Columbia
- ABAmit Bar‐Or
McGill University, Düsseldorf University Hospital, University of British Columbia, Heinrich Heine University Düsseldorf
- GCGıancarlo Comı
University of British Columbia, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf, Mylan (South Africa), Vita-Salute San Raffaele University
- GGGavin Giovannoni
Queen Mary University of London, University of British Columbia, Heinrich Heine University Düsseldorf, Düsseldorf University Hospital
- HHHans‐Peter Hartung
University of British Columbia, Heinrich Heine University Düsseldorf, Düsseldorf University Hospital
Topics & keywords
- Ocrelizumab
- Medicine
- Interferon beta-1a
- Multiple sclerosis
- Hazard ratio
- Internal medicine
- Confidence interval
- Gastroenterology